首页> Virology> Low-dose multivalent COVID-19 mRNA vaccines enhance broadly cross-reactive antibodies and protective immune responses of co-administered protein-based vaccines.

Low-dose multivalent COVID-19 mRNA vaccines enhance broadly cross-reactive antibodies and protective immune responses of co-administered protein-based vaccines.

导出 LinkOut

翻译打印收藏纠错

第一作者： Rong,Liu

第一单位： Center for Inflammation, Immunity & Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA, 30303, USA.

作者： Rong,Liu ^[1] ; Lila D,Patterson ^[2] ; Mahmuda,Yeasmin ^[1] ; Ki-Hye,Kim ^[1] ; Bo Ryoung,Park ^[1] ; Noopur,Bhatnagar ^[1] ; Jannatul Ruhan,Raha ^[1] ; Phillip,Grovenstein ^[1] ; Surya Sekhar,Pal ^[1] ; Chau Thuy Tien,Le ^[1] ; Chong Hyun,Shin ^[1] ; Lanying,Du ^[1] ; Mukesh,Kumar ^[3] ; Sang-Moo,Kang ^[4]

作者单位： Center for Inflammation, Immunity & Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA, 30303, USA. ^[1] Department of Biology, College of Arts and Sciences, Georgia State University, Atlanta, GA, 30303, USA. ^[2] Department of Biology, College of Arts and Sciences, Georgia State University, Atlanta, GA, 30303, USA. Electronic address: mkumar8@gsu.edu. ^[3] Center for Inflammation, Immunity & Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA, 30303, USA. Electronic address: skang24@gsu.edu. ^[4]

关键词 Adjuvant effects Influenza vaccine Low-dose multivalent mRNA vaccines SARS-CoV-2 variants